首页> 外文期刊>Nature medicine >Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.
【24h】

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.

机译:6q21的变异暗示PRDM1在霍奇金淋巴瘤之后由治疗引起的第二次恶性肿瘤的病因学中。

获取原文
获取原文并翻译 | 示例
           

摘要

Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.
机译:小儿霍奇金淋巴瘤的幸存者有放射治疗引起的第二恶性肿瘤(SMNs)的风险。我们在接受放射疗法治疗的霍奇金淋巴瘤幸存者中,发现了与SMN相关的6q21染色体上的两个变异,它们是儿童,而不是成人。变体包含与PRDM1的基础表达降低(编码含有1,具有ZNF域的PR结构域)的基础表达降低和辐射暴露后PRDM1蛋白诱导减弱相关的风险基因座。这些数据表明可能与PRDM1涉及放射治疗引起的SMNs病因的新的基因-暴露相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号